- Home
- LOAN vs MREO Comparison
LOAN vs MREO Comparison
Compare LOAN & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOAN | MREO |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 49.4M |
| IPO Year | 1999 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LOAN | MREO |
|---|---|---|
| Price | $4.44 | $0.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 16.5K | ★ 4.3M |
| Earning Date | 04-16-2026 | 05-11-2026 |
| Dividend Yield | ★ 10.06% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $8,666,307.00 | $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | $40.18 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.13 | $0.20 |
| 52 Week High | $5.85 | $2.94 |
Technical Indicators
Market Signals| Indicator | LOAN | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 61.00 | 55.48 |
| Support Level | $4.41 | $0.30 |
| Resistance Level | $4.48 | $0.36 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 83.91 | 47.95 |
Price Performance
Historical ComparisonAbout LOAN Manhattan Bridge Capital Inc
Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).